Primary Care Diabetes
Volume 1, Issue 1 , Pages 5-11 , February 2007

Is prevention of Type-2 diabetes feasible and efficient in primary care? A systematic PubMed review

  • Torsten Lauritzen

      Affiliations

    • Institute of Public Health, Department of General Practice, University of Aarhus, Denmark
    • Corresponding Author InformationCorresponding author at: Institute of Public Health, Department of General Practice, University of Aarhus, Vennelyst Boulevard 6, DK 8000 Århus, Denmark. Tel.: +45 89426047.
    • ,
  • Knut Borch-Johnsen

      Affiliations

    • Steno Diabetes Centre, Gentofte, Denmark
    • University of Aarhus, Denmark
    • ,
  • Annelli Sandbæk

      Affiliations

    • Institute of Public Health, Department of General Practice, University of Aarhus, Denmark

Received 24 April 2006 ,Revised 7 November 2006 ,Accepted 24 November 2006.

References 

  1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414–1431
  2. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted?. J. Intern. Med. 2000;247(3):301–310
  3. Mortality. I. American Diabetes Association, red. Diabetes 2001 Vital Statistics, American Diabetes Association, Alexandria, VA, 2001, pp. 77–85.
  4. Diabetes complications. I. American Diabetes Association, red. Diabetes 2001 Vital Statistics. American Diabetes Association, Alexandria, VA, 2001, pp. 43–74.
  5. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683–689
  6. Economic consequences of diabetes mellitus in the U.S. in 1997. American Diabetes Association. Diabetes Care 1998;21(2):296–309.
  7. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial 1. Lancet. 2006;368(9541):1096–1105
  8. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 2006;355(15):1551–1562
  9. Yamaoka K, Tango T. Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2005;28(11):2780–2786
  10. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537–544
  11. Wein P, Beischer N, Harris C, Permezel M. A trial of simple versus intensified dietary modification for prevention of progression to diabetes mellitus in women with impaired glucose tolerance. Aust. NZ J. Obstet. Gynaecol. 1999;39(2):162–166
  12. Lindahl B, Nilsson TK, Jansson JH, Asplund K, Hallmans G. Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance. J. Intern. Med. 1999;246(1):105–112
  13. Oldroyd JC, Unwin NC, White M, Imrie K, Mathers JC, Alberti KG. Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Res. Clin. Pract. 2001;52(1):29–43
  14. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001;344(18):1343–1350
  15. Swinburn BA, Metcalf PA, Ley SJ. Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care. 2001;24(4):619–624
  16. Mensink M, Feskens EJ, Saris WH, de Bruin TW, Blaak EE. Study on Lifestyle Intervention and Impaired Glucose Tolerance Maastricht (SLIM): preliminary results after one year. Int. J. Obes. Relat. Metab. Disord. 2003;27(3):377–384
  17. Watanabe M, Yamaoka K, Yokotsuka M, Tango T. Randomized controlled trial of a new dietary education program to prevent type 2 diabetes in a high-risk group of Japanese male workers. Diabetes Care. 2003;26(12):3209–3214
  18. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002;346(6):393–403
  19. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–297
  20. Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care. 2005;28(3):736–744
  21. Anderson DC. Pharmacologic prevention or delay of type 2 diabetes mellitus. Ann. Pharmacother. 2005;39(1):102–109
  22. Davies MJ, Tringham JR, Troughton J, Khunti KK. Prevention of Type 2 diabetes mellitus. A review of the evidence and its application in a UK setting. Diabet. Med. 2004;21(5):403–414
  23. Sherwin RS, Anderson RM, Buse JB, Chin MH, Eddy D, Fradkin J, et al. Prevention or delay of type 2 diabetes. Diabetes Care. 2004;27(Suppl 1):S47–S54
  24. Jermendy G. Can type 2 diabetes mellitus be considered preventable?. Diabetes Res. Clin. Pract. 2005;68(Suppl 1):S73–S81
  25. Prisant LM. Preventing type II diabetes mellitus. J. Clin. Pharmacol. 2004;44(4):406–413
  26. Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, Andre P, Isnard F, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care. 1996;19(9):920–926
  27. Jarrett RJ, Keen H, Fuller JH, McCartney M. Worsening to diabetes in men with impaired glucose tolerance (“borderline diabetes”). Diabetologia. 1979;16(1):25–30
  28. Li CL, Pan CY, Lu JM, Zhu Y, Wang JH, Deng XX, et al. Effect of metformin on patients with impaired glucose tolerance. Diabet. Med. 1999;16(6):477–481
  29. Yang WY, Lin HW, Qi J. The preventive effect of acarbose and metformin on the IGT population from becomming diabetes mellitus. Chin. J. Endocrinol. Metab. 2001;17:131–136
  30. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes. 1980;29(1):41–49
  31. Keen H, Jarrett RJ, Ward JD, Fuller JH. Borderline diabetics and their response to tolbutamide. Adv. Metab. Disord. 1973;2:Suppl-31
  32. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP–NIDDM randomised trial. Lancet. 2002;359(9323):2072–2077
  33. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP–NIDDM trial. JAMA. 2003;290(4):486–494
  34. Kaiser T, Sawicki PT. Acarbose for patients with hypertension and impaired glucose tolerance. JAMA. 2003;290(23):3066–3069
  35. Kaiser T, Sawicki PT. Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP–NIDDM data. Diabetologia. 2004;47(3):575–580
  36. Sawicki PT, Kaiser T. Response to Chiasson et al.: Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP–NIDDM Trial data. Diabetologia. 2004;47(6):976–977
  37. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP–NIDDM Trial data. Diabetologia. 2004;47(6):969–975
  38. Holman RR, North BU, Turnbridge FKE. Possible prevention of type 2 diabetes with acarbose or metformin. Diabet. Med. 2000;(17):S1
  39. Holman RR, Blackwell L, Stratton IM, Manley SE, Tucker L, Frighi V. Six-year results from early diabetes intervention trial. Diabet. Med. 2003;20:S15
  40. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002;51(9):2796–2803
  41. Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes. Metab. 2004;6(4):280–285
  42. Tuomilehto J, Wareham NJ. Glucose lowering and diabetes prevention: are they the same?. Lancet. 2006;368(9543):1218–1219
  43. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–161
  44. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch. Intern. Med. 2000;160(9):1321–1326
  45. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N. Engl. J. Med. 2005;353(20):2111–2120
  46. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin–Angiotensin system. Drugs. 2004;64(22):2537–2565
  47. Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care. 2005;28(9):2261–2266
  48. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care. 2004;27(1):247–255
  49. Ingelfiinger JR, Solomon CG. Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance—is there still hope?. N. Engl. J. Med. 2006;355(15):1608–1610
  50. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann. Intern. Med. 2005;142(5):323–332
  51. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann. Intern. Med. 2005;143(4):251–264
  52. Engelgau MM. Trying to predict the future for people with diabetes: a tough but important task. Ann. Intern. Med. 2005;143(4):301–302
  53. Brandeau ML. Modeling complex medical decision problems with the Archimedes model. Ann. Intern. Med. 2005;143(4):303–304
  54. Herman WH, Hoerger TJ, Hicks K, Brandle M, Sorensen SW, Zhang P, et al. Managing people at high risk for diabetes. Ann. Intern. Med. 2006;144(1):66–67
  55. Eddy D, Schlessinger L, Kahn R. In response. Ann. Intern. Med. 2006;144:67–68
  56. Lauritzen T, Mainz J, Lassen JF. From science to everyday clinical practice. Need for systematic evaluation of research findings. Scand J. Prim. Health Care. 1999;17(1):6–10
  57. Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet. 1983;1(8318):200–204
  58. Christensen JO, Sandbaek A, Lauritzen T, Borch-Johnsen K. Population-based stepwise screening for unrecognised Type 2 diabetes is ineffective in general practice despite reliable algorithms. Diabetologia. 2004;47(9):1566–1573
  59. De BG, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice 7. Eur. Heart J. 2003;24(17):1601–1610
  60. Engberg M, Christensen B, Karlsmose B, Lous J, Lauritzen T. General health screenings to improve cardiovascular risk profiles: a randomized controlled trial in general practice with 5-year follow-up. J. Fam. Pract. 2002;51(6):546–552

PII: S1751-9918(06)00009-X

doi: 10.1016/j.pcd.2006.11.001

Primary Care Diabetes
Volume 1, Issue 1 , Pages 5-11 , February 2007

Article Tools